Print page      E-mail page

Press Releases = Add Release to Briefcase Year: All Years 2008 2007 2006 2005 2004 2003 2002 All Releases Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update Jul 31, 2008 19.8 KB   SOUTH SAN FRANCISCO, Calif., July 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the second quarter ended June 30, 2008. "Our strategy and focus are to develop picoplatin a...   Read more Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium Jul 31, 2008 10.7 KB   SOUTH SAN FRANCISCO, Calif., July 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present information on platinum resistance at the Fourth Annual Moores UCSD Cancer Center Translational Oncology Symposium o...   Read more Poniard Pharmaceuticals Announces Upcoming Conference Participation Jul 29, 2008 10.5 KB   SOUTH SAN FRANCISCO, Calif., July 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Ronald A. Martell, president and chief operating officer, will participate in two upcoming conferences in August during which he will provide...   Read more Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 Jul 24, 2008 10.6 KB   SOUTH SAN FRANCISCO, Calif., July 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will hold a conference call to discuss the Company's second quarter results and provide a corporate update, including an update on the cli...   Read more Poniard Pharmaceuticals Appoints Janet R. Rea to Vice President, Regulatory Affairs and Quality Jul 10, 2008 12.0 KB   SOUTH SAN FRANCISCO, Calif., July 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has appointed Janet R. (nee Christensen) Rea, MSPH, RAC, as vice president, regulatory affairs and quality. Prior to joining Poniard, ...   Read more Poniard Pharmaceuticals to Present at the 7th Annual Needham Biotechnology and Medical Technology Conference Jun 5, 2008 10.3 KB   SOUTH SAN FRANCISCO, Calif., June 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference o...   Read more Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer Jun 1, 2008 14.2 KB   SOUTH SAN FRANCISCO, Calif. and CHICAGO, June 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced positive preliminary results from its ongoing randomized Phase 2 clinical trial in patients with metastatic colorectal cancer (CRC) and...   Read more Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer Jun 1, 2008 14.1 KB   SOUTH SAN FRANCISCO, Calif. and CHICAGO, June 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced safety and efficacy results from a previously unpublished Phase 1 clinical trial of picoplatin and liposomal doxorubicin in patients wi...   Read more Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer May 31, 2008 13.3 KB   SOUTH SAN FRANCISCO, Calif. and CHICAGO, May 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today presented preliminary safety and efficacy data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone...   Read more Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board May 28, 2008 15.8 KB   SOUTH SAN FRANCISCO, Calif., May 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the appointment of four additional members to its Clinical Advisory Board to help guide the Company's expanding clinical development strategy for p...   Read more Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting May 15, 2008 14.3 KB   SOUTH SAN FRANCISCO, Calif., May 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present data from three clinical trials of picoplatin, in various tumor types and combinations, at poster sessions during the...   Read more Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute May 14, 2008 13.0 KB   SOUTH SAN FRANCISCO, Calif., and LA JOLLA, Calif., May 14, 2008 /PRNewswire- FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, and The Scripps Research Institute, a non-profit biomedical research organization, today announced that an agreement has been executed licen...   Read more Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer May 6, 2008 14.1 KB   SOUTH SAN FRANCISCO, Calif., May 6, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating picoplatin combination chemotherapy for the first-line treatment o...   Read more Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update May 6, 2008 20.0 KB   SOUTH SAN FRANCISCO, Calif., May 6, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the first quarter ended March 31, 2008. "During the first quarter, we made significant progre...   Read more Poniard Pharmaceuticals Announces Upcoming Conference Participation May 1, 2008 10.2 KB   SOUTH SAN FRANCISCO, Calif., May 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will participate in two upcoming conferences in May: -- The Leerink Swann "Conquering Cancer ...   Read more Poniard Pharmaceuticals to Host First Quarter 2008 Financial Results Conference Call on May 6 Apr 29, 2008 10.6 KB   SOUTH SAN FRANCISCO, Calif., April 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will hold a conference call to discuss the Company's first quarter results and provide a corporate update, including an update on the cli...   Read more Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit Apr 23, 2008 13.3 KB   SOUTH SAN FRANCISCO, Calif., April 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that final efficacy results from its Phase 2 clinical trial of picoplatin confirming previously announced interim results showing a survival bene...   Read more Poniard Pharmaceuticals and AltheaDx Sign Agreement Apr 14, 2008 12.5 KB   SOUTH SAN FRANCISCO, Calif., April 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has selected AltheaDx, Inc.'s Express Pathway program to identify molecular signatures which may be correlated to platinum resistance. ...   Read more Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial Apr 13, 2008 14.3 KB   SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that an analysis of data from its ongoing Phase 1 clinical trial of an oral formulation of picoplatin in patients with solid tumors...   Read more Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference Apr 9, 2008 12.6 KB   SOUTH SAN FRANCISCO, Calif., April 9, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that data from a Phase 2 trial of picoplatin, the Company's lead product candidate, in patients with small cell lung cancer (SCLC) will be p...   Read more Showing 1-20 of 181 releases Page: 1 2 3 4 5 6 7 8 9 10  See Next 20

Stock Information PARD - (NASD) $4.15   + 0.10 Aug 21, 2008 3:33 PM ET  Shareholder Tools Investor Briefcase Investor Kit News & Event Alerts Download Library Glossary Investor FAQs News Feeds Investor site Section only Quotes delayed at least 20 minutes. Information provided by TurboFeed.